Argentina approves weekly subcutaneous hemophilia therapy; trial shows reduced bleeding

Argentina's ANMAT approved a weekly subcutaneous treatment for hemophilia A/B in patients 12+, following an international trial demonstrating significant bleeding reduction. This marks a shift from intravenous prophylaxis, improving convenience and adherence. The approval is a regulatory milestone but does not yet indicate market access or pricing.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works